سعر افاكسيم 80 وحدة /0.5مل سرنجة 2022

Paediatric inactivated, adsorbed hepatitis A vaccine (GBM strain) 80 antigen units per 0.5 ml, one pre-filled syringe for intramuscular injection; for children aged 12 months to 15 years (Sanofi Pasteur, France; imported).

• Active immunization against infection caused by hepatitis A virus in children aged from 12 months to 15 years inclusive (indication assessed and approved by the EDA)Population: Children aged 12 months to 15 yearsEgyptian Drug Authority (EDA)
• Active immunization against hepatitis A virus infection in persons 12 months to 15 years of age inclusive; primary immunization or booster after AVAXIM-Pediatric or similar hepatitis A vaccinesPopulation: Persons 12 months to 15 years of ageHealth Canada Drug Product Database (product monograph PDF)

• Most common: injection-site pain (13.4%) and abnormal crying (13.0%) after the first dose; injection-site pain (9.8%) and malaise (6.3%) after the second dose.International label, same product · Health Canada Drug Product Database (product monograph PDF)

• Hypersensitivity to this vaccine after previous administration or to any ingredient, including non-medicinal ingredients (e.g. formaldehyde, 2-phenoxyethanol, neomycin residue) or container components.International label, same product · Health Canada Drug Product Database (product monograph PDF)

• Postpone vaccination in acute or febrile disease (low-grade fever is usually not a reason to postpone). Have epinephrine available for anaphylaxis; syncope can occur around vaccination.International label, same product · Health Canada Drug Product Database (product monograph PDF)
• Give intramuscular injections with caution in bleeding disorders or anticoagulant therapy. Immunocompromised persons may not respond adequately; vaccination during incubation may not prevent hepatitis A; no protection against other hepatitis viruses; may not protect 100% of recipients.International label, same product · Health Canada Drug Product Database (product monograph PDF)

• Immune globulinMay be given simultaneously at separate sites with separate syringes; seroconversion is not modified but antibody titres could be lower.Health Canada Drug Product Database (product monograph PDF)
• Immunosuppressive treatmentsMay interfere with the development of the expected immune response.Health Canada Drug Product Database (product monograph PDF)

• Data in pregnant women are limited and administration during pregnancy is not recommended; give only if clearly needed after a benefit-risk assessment.International label, same product · Health Canada Drug Product Database (product monograph PDF)
• Not known whether excreted in human milk; use caution in nursing mothers.International label, same product · Health Canada Drug Product Database (product monograph PDF)

• Hepatitis A virus, GBM strain (inactivated): Induces the production of specific anti-hepatitis A virus antibodies (active immunisation).